Back to results
US 12,648,963 B2Granted
MiR200c-EpCAM axis reprogramed immune cells for enhanced anti-tumor function
AssigneesMemorial Sloan Kettering Cancer Center, Memorial Hospital for Cancer and Allied Diseases, Sloan-Kettering Institute for Cancer Research
InventorsMorgan Huse, Minggang Zhang
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions, kits, and methods for manufacturing cells for adoptive cell therapy comprising engineered immune cells that overexpress miR200c and/or EpCAM.
Claims8
An engineered immune cell comprising a non-endogenous expression vector comprising the miR200c nucleic acid sequence of SEQ ID NO:
- 25 and a non-endogenous expression vector comprising the EpCAM nucleic acid sequence of SEQ ID NO:
- 27 or a nucleic acid encoding the EpCAM polypeptide of SEQ ID NO:
- 29 wherein the engineered immune cell is a lymphocyte, a myeloid cell, a T cell, a B cell, a tumor infiltrating lymphocyte, or a natural killer cell and wherein the engineered immune cell is from an autologous donor or an allogenic donor.
Dependencies are inferred from the claim text.